Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2025)

Historic EBT for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$45.1 million.

  • Maravai Lifesciences Holdings' EBT rose 7377.25% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$218.0 million, marking a year-over-year decrease of 14946.69%. This contributed to the annual value of -$261.5 million for FY2024, which is 14232.91% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its EBT stood at -$45.1 million for Q3 2025, which was up 7377.25% from -$74.1 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' EBT ranged from a high of $656.2 million in Q4 2023 and a low of -$172.1 million during Q3 2024
  • Moreover, its 5-year median value for EBT was -$4.5 million (2023), whereas its average is $66.7 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' EBT soared by 2144844.9% in 2021 and then tumbled by 73715.41% in 2024.
  • Maravai Lifesciences Holdings' EBT (Quarter) stood at $144.7 million in 2021, then tumbled by 33.74% to $95.9 million in 2022, then soared by 584.41% to $656.2 million in 2023, then tumbled by 107.02% to -$46.1 million in 2024, then increased by 2.01% to -$45.1 million in 2025.
  • Its EBT was -$45.1 million in Q3 2025, compared to -$74.1 million in Q2 2025 and -$52.7 million in Q1 2025.